Current trends and investigative developments in celiac disease

Immunological Investigations

Volumn 42, Issue 4, 2013, Pages 273-284

  Samaşca, Gabriel ^a   Sur, Genel ^a   Lupan, Iulia ^b  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b BABE BOLYAI UNIVERSITY   (Romania)

Author keywords

Celiac; New investigations; Treatment

Indexed keywords

ACYLTRANSFERASE INHIBITOR; ALV 003; COPOLYMER; EPITOPE; GASTROINTESTINAL AGENT; GLIADIN; GLUTEN; LARAZOTIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A1; MONOCLONAL ANTIBODY G12; NEXVAX 2; PEPTIDE ANTIBODY; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2 INHIBITOR; PROTEINASE; TRAFICET; TRANSCRIPTOME; UNCLASSIFIED DRUG; VACCINE; VERCIRNON;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CELIAC DISEASE; CELL AGGLUTINATION; DRUG EFFICACY; DRUG RESPONSE; ENZYME ACTIVITY; EXPERIMENTAL THERAPY; GENE EXPRESSION PROFILING; GLUTEN FREE DIET; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEOMICS; SINGLE DRUG DOSE; TIGHT JUNCTION; TOXICITY TESTING; TRANSCRIPTOMICS; VACCINATION;

ANIMALS; CELIAC DISEASE; DIET, GLUTEN-FREE; GLIADIN; HUMANS; TRANSGLUTAMINASES;

EID: 84875947558     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820139.2013.777074     Document Type: Article

References (48)

1. Aziz, I., Evans, K. E., Papageorgiou, V., Sanders, D. S. (2011). Are patients with coeliac disease seeking alternative therapies to a gluten-free diet? J. Gastrointestin. Liver Dis. 20:27-31.
2. Badarau, E., Collighan, R. J., Griffin, M. (2011). Recent advances in the development of tissue transglutaminase (TG2) inhibitors. Amino Acids 44:119-27.
3. Bayardo, M., Punzi, F., Bondar, C., Chopita, N., Chirdo, F. (2012). Transglutaminase 2 expression is enhanced synergistically by interferon-γ and tumour necrosis factor-α in human small intestine. Clin. Exp. Immunol. 168:95-104.
4. Caron, N. S., Munsie, L. N., Keillor, J. W., Truant, R. (2012). Using FLIM-FRET to Measure Conformational Changes of Transglutaminase Type 2 in Live Cells. PLoS One 7:e44159.
5. Cederborg, A. C., Hultman, E., Magnusson, K. F. (2012). Living with children who have coeliac disease: a parental perspective. Child Care Health Dev. 38:484-489
6. Comino, I., Real, A., de Lorenzo, L., Cornell, H., López-Casado, M. Á., Barro, F., Lorite, P., Torres, M. I., Cebolla, A., Sousa, C. (2011). Diversity in oat potential immunogeni-city: basis for the selection of oat varieties with no toxicity incoeliac disease. Gut 60:915-922.
7. Comino, I., Real, A., Gil-Humanes, J., Pistón, F., de Lorenzo, L., Moreno, M. D., López-Casado, M. A., Lorite, P., Cebolla, A., Torres, M. I., Barro, F., Sousa, C. (2012). Significant differences in coeliac immunotoxicity of barley varieties. Mol. Nutr. Food Res. 56:1697-1707.
8. Crespo Pérez, L., Castillejo de Villasante, G., Cano Ruiz, A., León, F. (2012). Non-dietary therapeutic clinical trials in coeliac disease. Eur. J. Intern. Med. 23:9-14.
9. De Re, V., Simula, M. P., Canzonieri, V., Cannizzaro, R. (2010). Proteomic analyses lead to a better understanding of celiac disease: focus on epitope recognition and auto-antibodies. Dig. Dis. Sci. 55:3041-3046.
10. Diaz-Amigo, C., Popping, B. (2012). Gluten and gluten-free: issues and considerations of labeling regulations, detection methods, and assay validation. J. AOAC Int. 95: 337-348.
11. Ehren, J., Morón, B., Martin, E., Bethune, M. T., Gray, G. M., Khosla, C. (2009). A food-grade enzyme preparation with modest gluten detoxification properties. PLoS One 4:e6313.
12. Eksteen, B., Adams, D. H. (2010). GSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn's disease. IDrugs 13: 472-481.
13. Ferranti, P., Mamone, G., Picariello, G., Addeo, F. (2007). Mass spectrometry analysis of gliadins in celiac disease. J. Mass Spectrom. 42:1531-1548.
14. Ferretti, G., Bacchetti, T., Masciangelo, S., Saturni, L. (2012). Celiac disease, inflammation and oxidative damage: a nutrigenetic approach. Nutrients4:243-257.
15. Freeman HJ. 2012. Celiac disease and selected long-term health issues. Maturitas 73:206-211.
16. Gopalakrishnan, S., Durai, M., Kitchens, K., Tamiz, A. P., Somerville, R., Ginski, M., Paterson, B. M., Murray, J. A., Verdu, E. F., Alkan, S. S., Pandey, N. B. (2012a). Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides 35:86-94.
17. Gopalakrishnan, S., Tripathi, A., Tamiz, A. P., Alkan, S. S., Pandey, N. B. (2012b). Larazotide acetate promotes tight junction assembly in epithelial cells. Peptides 35:95-101.
18. Kasarda, D. D., Dupont, F. M., Vensel, W. H., Altenbach, S. B., Lopez, R., Tanaka, C. K., Hurkman, W. J. (2008). Surface-associated proteins of wheat starch granules: Suitability of wheat starch for celiac patients. J. Agric. Food Chem. 56:10292-10302.
19. Kaukinen, K., Ilus, T., Vornanen, M., Collin, P. (2012). When gluten-free diet does not cure celiac disease. Duodecim 128:945-951.
20. Koning F. (2012). Celiac disease: quantity matters. Semin Immunopathol 34: 541-9
21. Lähdeaho, M. L., Lindfors, K., Airaksinen, L., Kaukinen, K., Mäki, M. (2012). Recent advances in the development of new treatments for celiac disease. Expert Opin. Biol. Ther. 12:1589-1600.
22. Leffler, D. A., Kelly, C. P., Abdallah, H. Z., Colatrella, A. M., Harris, L. A., Leon, F., Arterburn, L. A., Paterson, B. M., Lan, Z. H., Murray, J. A. (2012). A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. Am. J. Gastroenterol. 107:1554-1562.
23. Li, J., Wang, S., Li, S., Ge, P., Li, X., Ma, W., Zeller, F. J., Hsam, S. L., Yan, Y. (2012). Variations and classification of toxic epitopes related to celiac disease among α-gliadin genes from four Aegilops genomes. Genome 55:513-521.
24. Luciani, A., Villella, V. R., Vasaturo, A., Giardino, I., Pettoello-Mantovani, M., Guido, S., Cexus, O. N., Peake, N., Londei, M., Quaratino, S., Maiuri, L. (2010). Lysosomal accumulation of gliadin p31-43 peptide induces oxidative stress and tissue transglutaminase-mediated PPARgamma downregulation in intestinal epithelial cells and coeliac mucosa. Gut 59:311-319.
25. Mamone, G., Camarca, A., Fierro, O., Sidney, J., Mazzarella, G., Addeo, F., Auricchio, S., Troncone, R., Sette, A., Gianfrani, C. (2012). Immunogenic peptides can be detected in whole gluten by transamidating highly susceptible glutamine residues: implication for searching of gluten-free cereals. J Agric Food Chem 61:747-54.
26. Mamone, G., Picariello, G., Addeo, F., Ferranti, P. (2011). Proteomic analysis in allergy and intolerance to wheat products. Expert Rev. Proteomics 8:95-115.
27. McAllister, C.S., Kagnoff, M.F.(2012). The immunopathogenesisof celiac disease reveals possible therapies beyond the gluten-free diet. Semin. Immunopathol. 34:581-600.
28. McSorley, H. J., Gaze, S., Daveson, J., Jones, D., Anderson, R. P., Clouston, A., Ruyssers, N. E., Speare, R., McCarthy, J. S., Engwerda, C. R., Croese, J., Loukas, A. (2011). Suppression of inflammatory immune responses in celiac disease by experimental hookworm infection. PLoS One 6:e24092.
29. Mitea, C., Havenaar, R., Drijfhout JW, Edens L, Dekking L, Koning F. 2008. Efficient degradation of gluten by a prolyl endoprotease in a gastrointestinal model: implications for coeliac disease. Gut 57: 25-32.
30. Mitea, C., Salentijn, E. M., van Veelen, P., Goryunova, S. V., van der Meer, I. M., van den Broeck, H. C., Mujico, J. R., Monserrat, V., Gilissen, L. J., Drijfhout, J. W., Dekking, L., Koning, F., Smulders, M. J. (2010). A universal approach to eliminate antigenic properties of alpha-gliadin peptides in celiac disease. PLoS One 5: e15637.
31. Morón, B., Bethune, M. T., Comino, I., Manyani, H., Ferragud, M., López, M. C., Cebolla, A., Khosla, C., Sousa, C. (2008). Toward the assessment of food toxicity for celiac patients: characterization of monoclonal antibodies to a main immunogenic gluten peptide. PLoS One 3:e2294.
32. Pinier, M., Fuhrmann, G., Galipeau, H. J., Rivard, N., Murray, J. A., David, C. S., Drasarova, H., Tuckova, L., Leroux, J. C., Verdu, E. F. (2012). The copolymer P (HEMA-co-SS) binds gluten and reduces immune response in gluten-sensitized mice and human tissues. Gastroenterology 142:316-325.
33. Pinier, M., Verdu, E. F., Nasser-Eddine, M., David, C. S., Vézina, A., Rivard, N., Leroux, J. C. (2009). Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium. Gastroenterology 136:288-298.
34. Rashtak, S., Murray, J. A. (2012). Review article: coeliac disease, new approaches to therapy. Aliment Pharmacol. Ther. 35:768-781.
35. Rauhavirta, T., Oittinen, M., Kivistö, R., Männistö, P. T., Garcia-Horsman, J. A., Wang, Z., Griffin, M., Mäki, M., Kaukinen, K., Lindfors, K. (2012). Are transglutaminase 2 inhibitors able to reduce gliadin-induced toxicity related to celiac disease? A proof-of-concept study. J. Clin. Immunol.33:134-42.
36. Richman, E. (2012). The safety of oats in the dietary treatment of coeliac disease. Proc. Nutr. Soc. 71:534-537.
37. Salentijn, E. M., Mitea, D. C., Goryunova, S. V., Van der Meer, I. I., Padioleau, I., Gilissen, L. J., Koning, F., Smulders, M. J. (2012). Celiac disease T-cell epitopes from gamma-gliadins: immunoreactivity depends on the genome of origin, transcript frequency, and flanking protein variation. BMC Genomics 13:277.
38. Samasca, G., Iancu, M., Pop, T., Butnariu, A., Andreica, M., Cristea, V., Dejica, D. (2011). Importance of the educational environment in the evolution of celiac disease. Lab Med. 42:497-501.
39. Sapone, A., Bai, J. C., Ciacci, C., Dolinsek, J., Green, P. H., Hadjivassiliou, M., Kaukinen, K., Rostami, K., Sanders, D. S., Schumann, M., Ullrich, R., Villalta, D., Volta, U., Catassi, C., Fasano, A. (2012). Spectrum of gluten-related disorders: Consensus on new nomenclature and classification. BMC Med 10:13.
40. Siegel, M., Garber, M. E., Spencer, A. G., Botwick, W., Kumar, P., Williams, R. N., Kozuka, K., Shreeniwas, R., Pratha, V., Adelman, D. C. (2012). Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials. Dig. Dis. Sci. 57:440-450.
41. Silano, M., Vincentini, O., Luciani, A., Felli, C., Caserta, S., Esposito, S., Villella, V. R., Pettoello-Mantovani, M., Guido, S., Maiuri, L. (2012). Early tissue transglutaminase-mediated response underlies K562(S)-cell gliadin-dependent agglutination. Pediatr. Res. 71:532-538.
42. Skylas, D. J., Mackintosh, J. A., Cordwell, S. J., Basseal, D. J., Walsh, B. J., Harry, J., Blumenthal, C., Copeland, L., Wrigley, C. W., Rathmell, W. 2000. Proteome approach to the characterization of protein composition in the developing and mature wheat grain endosperm. J. Cereal Sci. 32:169-188.
43. Thompson, T., Lee, A. R., Grace, T. (2010). Gluten contamination of grains, seeds, and flours in the United States: a pilot study. J. Am. Diet Assoc. 110:937-940.
44. Tjon, J. M., van Bergen, J., Koning, F. (2010). Celiac disease: How complicated can it get? Immunogenetics 62:641-651.
45. Tye-Din, J. A., Anderson, R. P., French, R. A., Brown, G. J., Hodsman, P., Siegel, M., Botwick, W., Shreeniwas, R. (2010). The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo. Clin. Immunol. 134: 289-295.
46. Vincentini, O., Maialetti, F., Gazza, L., Silano M., Dessi, M., De Vincenzi, M., Pogna, N. E. (2007). Environmental factors of celiac disease: cytotoxicity of hulled wheat species Triticum monococcum, T. turgidum ssp. dicoccum and T. aestivum ssp. spelta. J. Gastroenterol. Hepatol. 22:1816-1822.
47. Wan, Y., Poole, R. L., Huttly, A. K., Toscano-Underwood, C., Feeney, K., Welham, S., Gooding, M. J., Mills, C., Edwards, K. J., Shewry, P. R., Mitchell, R. A. (2008). Transcriptome analysis of grain development in hexaploid wheat. BMC Genomics 9: 121.
48. Wang, S., Shen, X., Ge, P., Li, J., Subburaj, S., Li, X., Zeller, F. J., Hsam, S. L., Yan, Y. (2012). Molecular characterization and dynamic expression patterns of two types of γ-gliadin genes from Aegilops and Triticum species. Theor. Appl. Genet. 125: 1371-1384.